

PUBLISHED BY  
THE MEDICAL RESEARCH SOCIETY AND THE BIOCHEMICAL SOCIETY

Printed in Great Britain by Spottiswoode Ballantyne Ltd.  
Colchester and London

# Volume 59

## SUBJECT INDEX

First and last page numbers of papers to which entries refer are given.  
Page numbers marked with an asterisk refer to Editorial Reviews.

- Absorption**  
  amino acids 285–287, 373–380  
  carbohydrate gelling agents 373–380  
  dipeptide 285–287  
  galactose 317–327  
  monosaccharide 373–380
- Accidental hypothermia** 19–27
- Acetoacetate oxidation, perfused heart** 289–292
- Acidosis, heavy exercise** 85–91\*
- Adenosine 3':5'-phosphate, adipose tissue lipolysis** 199–201
- Adipose tissue, cyclic AMP** 199–201
- Adolescence, nitrogen metabolism** 13–18
- Adrenergic resistance, salbutamol** 155–166
- $\alpha$ -Adrenoreceptors**  
  indomethacin 397–400  
  indoramin 497–500
- $\beta$ -Adrenoreceptor blockade**  
  chronic 207–209  
  indomethacin 397–400
- Age, diazepam pharmacokinetics** 479–483
- Aged patients, hypothermia** 19–27
- Airway resistance, salbutamol** 155–161
- Airways, tracheobronchial tree** 79–84\*
- Albumin, transvascular flux in oedema** 105–113
- Alloxan, transvascular albumin flux** 105–113
- Aldosterone**  
  chronic frusemide therapy 443–449  
  renin and prostaglandin E 55–62
- Ambulatory monitoring** 497–500
- Amino acids**  
  absorption 285–287  
  branched-chain 173–181, 275–283  
  hypothermia 19–27  
  infused leucine 173–181
- Amino [ $^{15}\text{N}$ ]nitrogen** 13–18
- Angiotensin**  
  hypotensive effect of captopril 451–456  
  renin–angiotensin–aldosterone axis 55–62
- Angiotensin I-converting enzyme** 451–456
- Angiotensin II, captopril** 451–456
- Ankylosing spondylitis, HLA-B27** 405–410\*
- Aorta, thoracic, prostacyclin-like activity** 369–372
- Apoproteins (A I and A II), metabolism** 359–367
- Arrhythmia, quantification** 207–209
- Arteriovenous differences, hypothermia** 19–27
- Asthma, salbutamol** 155–161
- Bacteriology, intestinal, parenteral feeding** 329–336
- Baroreflex, experimental hypertension** 347–352
- Bicarbonate, heavy exercise** 85–91\*
- Bile acid, obesity** 203–206
- Blood platelets**  
   $^{111}\text{In}$ -labelled in glomerulonephritis 147–150  
  thromboxane and malondialdehyde 131–135
- Blood pressure**  
  ambulant 497–500  
  captopril 451–456  
  volume expansion 411–421, 423–433
- Blood volume, expansion** 411–421, 423–433
- Bone, trabecular and cortical** 393–395
- Bone loss, calcium balance in women** 137–142
- Brain, uptake of leucine** 173–181
- Bronchial narrowing, pulmonary oedema** 93–103
- Bronchofibrescope** 79–84\*
- Calcium ( $^{47}\text{Ca}$ ) absorption, intestinal** 169–172
- Calcium balance, bone loss** 137–142
- Calcium metabolism, bone disorders** 215–223\*
- Captopril (SQ 14 225), hypotensive effect** 451–456
- Carbohydrate gelling agent** 373–380
- Catecholamines, tetraplegia** 251–256
- Chenodeoxycholic acid, obesity** 203–206
- Cholesterol, insulin in diabetes** 71–74
- Cholic acid, obesity** 203–206
- Cirrhosis, forearm glucose uptake** 191–198
- Cobalamins, nitrous oxide** 151–154\*
- Coitus, propranolol effects** 231–236
- Collagen** 215–223\*
- Colon**  
  mucosal peptide hormones 457–462  
  transepithelial potassium 29–39
- Computed tomography** 393–395
- Concanavalin A, binding** 385–387
- Core temperature, hypothermia** 19–27

- Cortisol, hypothermia 19–27  
 Creatinine excretion, myofibrillar protein breakdown 211–214  
 Cryoactivation, plasma renin 49–53  
 Cyclic AMP *see* Adenosine 3':5'-phosphate  
 Cytosol  
   properties in Pompe's disease 1–6  
   rectal mucosal biopsies 457–462  
  
 Deconvolution measurements 169–172  
 Diabetes  
   prostaglandin metabolism 63–66  
   serum high-density lipoprotein cholesterol 71–74  
 Diaphragm, bilateral paralysis 485–492  
 Diazepam, age on pharmacokinetics 479–483  
 Diet, vegetarian 509–511  
 Dietary fibre 373–380  
 25,26-Dihydroxycholecalciferol 257–263  
 2,3-Diphosphoglycerate  
   dialysis in uraemia 143–145  
   intra-erythrocytic by <sup>31</sup>P n.m.r. 225–230\*  
 Diuretic, frusemide 443–449  
 Diuretics, prostaglandin interaction 67–70  
 Diurnal variation, immunoreactive substance P 75–77  
 Dose–response, hypotension and captopril 451–456  
 Dumping syndrome, neurotensin 237–243  
 Dyspnoea, respiratory load detection 493–495  
  
 Encephalopathy, portal-systemic 173–181  
 Endoplasmic reticulum  
   density gradient localization 7–12  
   Pompe's disease 7–12  
   rectal mucosal biopsies 457–462  
 Enkephalin, vasopressin 501–503  
 Enterocutaneous fistula, urinary nitrogen 211–214  
 Enteroglucagon, dumping syndrome 237–243  
 Enzyme  
   inhibitors for renin assay 381–383  
   organelle markers 1–6  
   rectal mucosa 457–462  
 Erythrocyte  
   methylprednisolone 163–168  
   n.m.r. proton spectra 225–230\*  
 Ethinyloestradiol, prostacyclins 369–372  
*N*-Ethylmaleimide, proteolytic inhibitor 337–345  
 Exercise, metabolic acidosis 85–91\*  
  
 Fatty acids, metabolism during exercise 463–468  
 Femur fracture  
   bone loss, calcium balance 137–142  
   trabecular and cortical bone 393–395  
  
 Ferritin  
   glucosylation 385–387  
   source during infection 385–387  
   synthesis 385–387  
 Gases, radioactive, lung distribution 485–492  
 Gastric inhibitory polypeptide 237–243  
 Gastrointestinal hormones  
   gastric antrum 1–6  
   rectal mucosa 457–462  
   serotonin and motilin 505–508  
 Glomerulonephritis, chronic 147–150  
 Glucose  
   forearm arteriovenous difference in cirrhosis 191–198  
   hypothermia 19–27  
   metabolism during exercise 463–468  
 Glycerol  
   hypothermia 19–27  
   lipolysis index 463–468  
 Glycogen-storage disease, type II 7–12  
 Glycyl-L-leucine, transport kinetics 301–309  
  
 Haemodialysis, blood oxygen transport 143–145  
 Haemodynamics, cardiac failure 443–449  
 Haemoglobin, methylprednisolone 163–168  
 Heart  
   failure, myocardial infarction 115–121  
   frusemide 443–449  
   ischaemia, <sup>31</sup>P n.m.r. studies 225–230\*  
   propranolol-withdrawal syndrome 207–209  
 Hepatocytes, <sup>31</sup>P n.m.r. spectra 225–230\*  
 High-density lipoproteins  
   insulin in diabetes 71–74  
   primary hypertriglyceridaemia 359–367  
 High-molecular-weight renin 337–345  
 Histamine, ulcerative colitis 389–391  
 HLA histocompatibility antigen 405–410\*  
 Hydrogen ion, production in acidosis 85–91\*  
 25-Hydroxycholecalciferol 257–263  
 6-Hydroxydopamine, sympathectomy in spontaneous hypertension 123–129  
 Hydroxylysine, collagen metabolism 215–223\*  
 Hydroxyproline, collagen metabolism 215–223\*  
 25-Hydroxy-vitamin D, hyperbilirubinaemia 293–296  
 Hyperparathyroidism bone loss, calcium balance 137–142  
 Hypertension  
   neonatal sympathectomy 123–129  
   pre-eclampsia 49–53  
   renal, Goldblatt two-kidney one-clip 347–352  
 Hypertriglyceridaemia, apoprotein metabolism 359–367  
 Hypotension, haemorrhagic 105–113

- Hypothermia 19–27
- Hypoplasia, intestinal mucosal 317–327
- Immunoreactive substance P 75–77
- Indium (<sup>111</sup>In)-labelled platelets, glomerulonephritis 147–150
- Indomethacin  
adrenoreceptors 397–400  
renal prostaglandin system 67–70  
sickle cell anaemia 245–250
- Indoramin,  $\alpha$ -adrenoreceptor antagonist 497–500
- Infection, serum ferritin 385–387
- Inferior vena cava, prostacylin-like activity 369–372
- Injury, infused leucine removal 275–283
- Insulin  
hypothermia 19–27  
resistance 191–198
- Intestine  
adaptation to parenteral feeding 317–327, 329–336  
monosaccharide, amino acid transport 373–380
- Intra-articular hydrostatic pressure 41–48
- Jaundice, hyperbilirubinaemia 293–296
- Jejunum  
dipeptide absorption 285–287  
serotonin and motilin 505–508
- Joint, synovial, artificial effusion 41–48
- Kaliuresis, spironolactone on renal prostaglandins 67–70
- Ketone bodies  
hypothermia 19–27  
propionate metabolism 289–292
- Ketosis, propionate in disease 289–292
- Kidney  
hypervolaemia 183–189  
ischaemia, <sup>31</sup>P n.m.r. studies 225–230\*  
prostaglandins in diabetes mellitus 63–66  
regulation of sodium 435–441  
renin precursor 297–299  
sialic acid 401–404  
transplant 435–441
- Kidney function test 245–250
- Klebsiella pneumoniae*, ankylosing spondylitis 405–410\*
- Krypton (<sup>81m</sup>Kr, <sup>85m</sup>Kr), regional lung function 485–492
- Lactate  
cirrhosis 191–198  
fat metabolism 463–468  
heavy exercise 85–91\*, 463–468  
hypothermia 19–27
- Leucine, infusion 173–181, 275–283
- Leucocytes, zinc transport 353–357
- Lipolysis, cyclic AMP 199–201
- Lipoproteins, high-density  
insulin in diabetes 71–74  
primary hypertriglyceridaemia 359–367
- Lipoproteins, low-density, receptors 265–273
- Lithium, transepithelial 29–39
- Liver, <sup>31</sup>P-n.m.r. spectra of hepatocytes 225–230\*
- Liver disease  
cirrhosis 191–198  
Pompe's disease 7–12
- Loaded breathing, passive ventilation 493–495
- Low-density lipoprotein receptors 265–273
- Low-molecular-weight renin 337–345
- Lung  
mechanics 485–492  
open-chested ventilation 105–113  
prostaglandin in diabetes mellitus 63–66
- Lymphoblastoid cells, rosette-forming technique 265–273
- Lysosomes  
density gradient localization 7–12  
Pompe's disease 7–12  
rectal mucosa 457–462
- Malondialdehyde, thromboxane and blood platelets 131–135
- Mathematical analysis of clinical diagnosis 301–309
- Menopause bone loss, calcium balance 137–142
- Messenger RNA, renin precursor 297–299
- Methionine  
enkephalin analogue (DAMME) 501–503  
nitrous oxide 151–154\*
- N*<sup>ε</sup>-Methylhistidine excretion  
myofibrillar protein breakdown 211–214  
vegetarian diet 509–511
- Methylprednisolone, erythrocytes and haemoglobin 163–168
- Mitochondria  
density gradient localization 7–12  
Pompe's disease 7–12  
rectal mucosa 457–462
- Monosaccharide absorption, carbohydrate gelling agent 373–380
- Morphometry, bone loss and calcium balance 137–142
- Motilin  
dumping syndrome 237–243  
jejunum localization 505–508
- Mucociliary function, chronic diseases 79–84\*
- Mucosa, gastrointestinal  
gastric 1–6  
hypoplasia, hypofunction 317–327  
rectal 457–462

- Muscle, skeletal  
  leucine uptake 173–181  
  3-methylhistidine excretion 509–511  
  protein breakdown 211–214  
  pH during heavy exercise 85–91\*  
  superfused, n.m.r. studies 225–230\*
- Myocardial infarction, ventilatory pattern and drive 115–121
- Natriuretic factor 183–189
- Nephrectomy, dihydroxy metabolite 257–263
- Natriuresis  
  blood-volume expansion 411–421, 423–433  
  frusemide on renal prostaglandins 67–70
- Neurotensin, dumping syndrome 237–243
- Nitrous oxide, cobalamins 151–154\*
- Non-esterified fatty acids, hypothermia 19–27
- Noradrenaline, propranolol during coitus 231–236
- Norethisterone, prostacyclins 369–372
- Nuclear magnetic resonance, metabolism 225–230\*
- Obesity  
  cholesterol and bile acid metabolism 203–206  
  nitrogen metabolism 13–18
- Occlusion pressure 115–121
- Osteogenesis imperfecta, type I collagen disorder 215–223\*
- Osteoporosis, bone loss, calcium balance 137–142
- Oxygen affinity  
  methylprednisolone 163–168  
  uraemia 143–145
- Pancreas, parenteral nutrition 329–336
- Parenteral feeding, exclusive 329–336
- Peroxisomes  
  density gradient localization 1–6  
  rectal mucosa 457–462
- Pharmacodynamics, modelling drug response 311–315
- Pharmacokinetics, diazepam 479–483
- Pharmacokinetic parameters 311–315\*
- Plasma membrane  
  density gradient localization 7–12  
  Pompe's disease 7–12  
  rectal mucosa 457–462
- Platelets, blood  
  <sup>111</sup>In-labelled in glomerulonephritis 147–150  
  malondialdehyde and thromboxane 131–135
- Pompe's disease 7–12
- Posture  
  effect on immunoreactive substance P 75–77  
  head-up tilt in paraplegia 251–256
- Potassium, transepithelial 29–39
- Pregnancy, hypertension and plasma renin 49–53
- Propionate, metabolism in ketosis 289–292
- Protein metabolism, obese adolescents 13–18
- Propranolol  
  effects during coitus 231–236  
  withdrawal syndrome 207–209
- Prostacyclin activity 369–372
- Prostaglandin  
  indomethacin 397–400  
  metabolizing enzymes, diabetes 63–66  
  renal 55–62, 67–70
- Prostaglandin synthase 63–66
- Pseudomonas pyocyanea*, increased transvascular albumin flux 105–113
- Pulmonary oedema  
  airways 93–103  
  transvascular albumin flux 105–113
- Radioactive gases, lung distribution 485–492
- Radioimmunoassay circulating 25,26-dihydroxycholecalciferol 257–263
- Radioisotope kinetics, transepithelial <sup>43</sup>K 29–39
- Rectum, histamine release 389–391
- Regional lung volume, pulmonary oedema 93–103
- Renal prostaglandins  
  interaction of diuretics 67–70  
  renin–angiotensin–aldosterone relationship 55–62
- Renin  
  enzyme inhibitors 381–383  
  head-up tilt 251–256  
  precursors identified by mRNA 297–299  
  pregnancy 49–53  
  protein inhibitor 337–345  
  storage form 337–345
- Renin–angiotensin system  
  aldosterone and prostaglandins 55–62  
  congestive heart failure 443–449  
  neonatal sympathectomy 123–129  
  sodium excretion 435–441  
  spontaneous hypertension 123–129
- Respiratory exchange ratio, exercise 463–468
- Respiratory muscle fatigue 463–468
- Respiratory sensation 493–495
- Rheumatic diseases, HLA histocompatibility antigen 405–410\*
- Salbutamol, airway and metabolic resistance 155–161
- Serotonin, jejunum localization 505–508
- Sialic acid, kidney stone matrix 401–404
- Sickle cell anaemia, renal haemodynamics 245–250
- Skeletal muscle *see* Muscle, skeletal

- Sodium  
 balance, immunoreactive substance P 75-77  
 excretion 411-421, 423-433  
 intrarenal regulation 435-441  
 transepithelial, colon 29-39
- Spontaneous hypertension, neonatal sympathectomy 123-129
- Starvation, leucine removal 275-283
- Steroid balance, obesity 203-206
- Stomach, mucosal peptide hormones 1-6
- Sternomastoid muscle function 463-468
- Streptozotocin, induced diabetes 71-74
- Strontium (<sup>85</sup>Sr), deconvolution measurements 169-172
- Subcellular fractionation  
 gastric antral biopsies 1-6  
 jejunum 505-508  
 Pompe's disease 7-12  
 rectal mucosa 457-462  
 serotonin and motilin 505-508
- Sympathectomy, neonatal 123-129
- Sympathetic nervous system, tetraplegia 251-256
- Synovial fluid, artificial effusion absorption 41-48
- Tetraplegia, sympathetic nervous system 251-256
- Thoracic aorta, prostaglandin-like activity 369-372
- Thrombocytes *see* Platelets
- Thromboxane B<sub>2</sub>, blood platelets and malondialdehyde 131-135
- Tilt, vasopressin response 501-503
- Total parenteral nutrition, intestinal adaptations 317-327
- Tracheobronchial tree, clearance of particles 79-84\*
- Transplant, kidney 435-441
- Transport  
 affinity systems 301-309
- Transport (*continued*)  
 blood oxygen 143-145  
 intestinal 285-287  
 kinetics 301-309, 373-380  
 zinc 353-357
- Triglycerides, insulin in diabetes 71-74
- Tumour cells, pH difference by <sup>31</sup>P n.m.r. 225-230\*
- Ulcerative colitis, histamine 389-391
- Ultrafiltration, blood oxygen transport 143-145
- Ultraviolet radiation, 25-hydroxy-vitamin D 293-296
- Uraemia, dialysis and ultrafiltration 143-145
- Urea, sickle cell anaemia 245-250
- Vasopressin, response to tilt 501-503
- Vena cava, inferior, prostacyclin-like activity 369-372
- Ventilation  
 heavy exercise 85-91\*  
 passive 493-495  
 perfusion relationship 93-105  
 myocardial infarction 115-121  
 sternomastoid fatigue 463-468
- Ventilatory drive 115-121
- Vitamin B<sub>12</sub>, nitrous oxide 151-154\*
- Vitamin D deficiency,  
 dihydroxy metabolite 257-263
- Volume regulation 183-189
- Water  
 absorption, indomethacin and diuretics 67-70  
 immersion 55-62  
 interstitial volume 105-113
- Water immersion  
 renin-aldosterone and prostaglandin dissociation 55-62
- Zinc, transport in leucocytes 353-357